Donat Antonia, Xie Weixin, Jiang Shan, Brylka Laura Janina, Schinke Thorsten, Rolvien Tim, Frosch Karl-Heinz, Baranowsky Anke, Keller Johannes
Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany.
Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Inflamm Res. 2025 Mar 6;74(1):48. doi: 10.1007/s00011-025-02013-8.
OBJECTIVE: Osteoarthritis (OA) is one of the leading causes of disability in the aging population. While about 10% of the adult population is affected by OA, there is to date no curative treatment and joint replacement surgery remains the only option for treating end-stage OA. Previous studies found elevated levels of the chemokine C-X-C motif ligand 9 (CXCL9) in the synovial fluid of OA knees. However, the exact role of CXCL9 in OA progression is still unknown. METHODS: Female wild-type and Cxcl9-deficient mice were challenged with a unilateral anterior cruciate ligament transection (ACLT). Joint destruction in early and late stages of experimental OA was assessed using micro-CT scanning, histological scoring, histomorphometry, and gene expression analysis. RESULTS: Inactivation of Cxcl9 protected from cartilage destruction and osteophyte formation in post-traumatic OA in mice. Similarly, indices of joint inflammation including synovitis and expression of pro-inflammatory interleukin-1beta were reduced in OA knees of Cxcl9-deficient mice. However, bone erosion and pathophysiological changes in the subchondral bone compartment remained unaffected in Cxcl9-deficient mice with experimental OA. CONCLUSION: Our results point towards a pro-inflammatory role of CXCL9 in OA and identify a potential new target for the pharmacological treatment of OA.
Arthritis Res Ther. 2019-12-23
Am J Sports Med. 2024-3
Am J Sports Med. 2024-3
J Clin Med. 2022-10-12
Proc Natl Acad Sci U S A. 2020-7-27